applying these guidelines to individual families. Furthermore, these guidelines were not developed as a substitute for professional genetic counseling. Rather, they are intended to help health care providers identify individuals who may benefit from cancer
Search Results
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Mary B. Daly, Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P. Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R. Smith, Elizabeth Swisher, and Jeffrey N. Weitzel
Multigene Testing for Hereditary Cancer: When, Why, and How
Kenneth Offit
,” Dr. Offit stated at the outset of his talk. Currently, NCCN does not endorse routing multiplex testing outside of a research setting, and/or intensive genetic counseling regarding risks and benefits. The 2017 NCCN Clinical Practice Guidelines in
Gene Panel Testing for Inherited Cancer Risk
Michael J. Hall, Andrea D. Forman, Robert Pilarski, Georgia Wiesner, and Veda N. Giri
inherited cancer risk when first-line evaluation has been inconclusive All discussions must include the risks and benefits of gene panel testing in a genetic counseling setting, with informed consent reflecting the discussion. Choice of Laboratory
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
Featured Updates to the NCCN Guidelines
Mary B. Daly, Tuya Pal, Kara N. Maxwell, Jane Churpek, Wendy Kohlmann, Zahraa AlHilli, Banu Arun, Saundra S. Buys, Heather Cheng, Susan M. Domchek, Susan Friedman, Veda Giri, Michael Goggins, Andrea Hagemann, Ashley Hendrix, Mollie L. Hutton, Beth Y. Karlan, Nawal Kassem, Seema Khan, Katia Khoury, Allison W. Kurian, Christine Laronga, Julie S. Mak, John Mansour, Kevin McDonnell, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Dominique Rash, Gwen Reiser, Leigha Senter-Jamieson, Kristen Mahoney Shannon, Kala Visvanathan, Jeanna Welborn, Myra J. Wick, Marie Wood, Matthew B. Yurgelun, Mary A. Dwyer, and Susan D. Darlow
intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; provide genetics health care professionals with an updated tool for the assessment of
Diagnosis and Management of Rectal Cancer in Patients Younger Than 50 Years: Rising Global Incidence and Unique Challenges
Daenielle Lang and Kristen K. Ciombor
counseling, financial guidance, reproductive health, genetic counseling, nutrition, psychosocial distress, spirituality, and physical and mental well-being. 41 There should be discussion of fertility preservation with these patients of childbearing age prior
Germline and Somatic Mutations in Prostate Cancer for the Clinician
Heather H. Cheng, Alexandra O. Sokolova, Edward M. Schaeffer, Eric J. Small, and Celestia S. Higano
actionability of widespread genetic testing in early, low-risk prostate cancer settings without other risk factors remain unclear, and short-term unintended consequences include clinical confusion and low-yield depletion of limited genetic counseling resources
A Young Woman With Bilateral Breast Cancer: Identifying a Genetic Cause and Implications for Management
Monique A. de Bruin, James M. Ford, and Allison W. Kurian
bilateral breast cancer at a young age, she met NCCN criteria for BRCA1/2 mutation testing. 1 She underwent appropriate genetic counseling and then BRCA1/2 mutation testing by full sequencing, which was negative. BRCAnalysis Comprehensive Rearrangement
Counterpoint: Implementing Population Genetic Screening for Lynch Syndrome Among Newly Diagnosed Colorectal Cancer Patients—Will the Ends Justify the Means?
Michael J. Hall
, and by whom consent would be obtained in a population screening program remain unanswered. 7 , 9 , 13 Low provider knowledge of MSI/IHC and scarce genetic counseling resources 14 would likely leave many patients poorly informed about the
Genetic Kidney Cancer Syndromes
Thai H. Ho and Eric Jonasch
testing of selected genes based on renal cell carcinoma (RCC) histology: (A) clear cell, (B) papillary type I, (C) papillary type II, and (D) chromophobe. Persons with RCC aged 46 years or younger should be considered for genetic counseling and germline
Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course
Jocelyn S. Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles J. Zaloudek, Stefanie Ueda, Eric A. Collisson, and Barry S. Taylor
for genetic counseling, which revealed no family history of hereditable cancer. Plasma was sent for cell-free DNA (cfDNA) sequencing. 7 A baseline staging CT scan was obtained before the planned initiation of gemcitabine and nanoparticle albumin
